MYELODYSPLASTIC SYNDROME

This study tested whether adding pevonedistat to standard azacitidine helps people with certain blood cancers (MDS, CMML, or low-blast AML) live longer without their disease getting worse. About 450 adults at high risk of progression took part. The goal was to see if the combinat…

This study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…

This early-phase trial tested a mix of a cancer vaccine, chemotherapy, and immunotherapy in 8 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with low blast counts. The goal was to see if the combination is safe and helps the immune system fight cancer …

This early-phase study tested two drugs, bortezomib and lenalidomide, in 22 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) came back after a stem cell transplant. The main goal was to find the safest dose and see if the combination could reduce cancer…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients over 60 receiving a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see if these changes …

This early-phase study tested two immunotherapy drugs, nivolumab and ipilimumab, in 29 people whose acute myeloid leukemia or myelodysplastic syndrome came back or didn't respond after a donor stem cell transplant. The goal was to find the safest dose and see if the combination c…

This early-phase study tested a new drug combination (navitoclax, venetoclax, and decitabine) in 6 adults with high-risk myelodysplastic syndrome (MDS) that returned or didn't respond to initial treatment. The main goals were to find the safest dose and check for side effects. Th…

This early-phase trial tested a combination of two drugs, ibrutinib and lenalidomide, in people with myelodysplastic syndrome (MDS) who could not take or chose not to take standard treatments. The main goal was to find the safest dose and identify side effects. Only 4 people took…

This study tested the drug ustekinumab in 8 adults with a rare and severe form of intestinal Behçet's syndrome that also involves a blood disorder called myelodysplastic syndrome. The goal was to see if the drug could improve gut symptoms and control disease activity over 24 week…

This phase 2 trial tested whether adding ready-made donor natural killer (NK) cells to a standard stem cell transplant could safely reduce the chance of cancer coming back in people with high-risk myeloid cancers like AML, MDS, and CML. Twenty-four patients received the combinati…

This study tested a drug called guadecitabine combined with donor white blood cell infusions in 55 adults whose leukemia or MDS came back after a stem cell transplant. The goal was to see if the drug could help the donor cells fight the cancer more effectively. The treatment aims…

This study tested whether adding the drug itacitinib to the usual two-drug regimen (tacrolimus and sirolimus) could better prevent graft-versus-host disease (GVHD) in 59 adults with blood cancers (acute leukemia, myelodysplastic syndrome, or myelofibrosis) undergoing a donor stem…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by donor stem cells to help destroy c…

This completed study looked at 126 adults aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover …